Reports Q2 revenue $136.1M, consensus $132M. “We are pleased to report a record quarter with revenue of $136.1 million, as sales from our platforms and disposables were the strongest they’ve ever been,” said Moshe Mizrahy, CEO. “Our commitment to innovation supports our growth and leads to a solid brand recognition within the aesthetics industry.” Shakil Lakhani, President of InMode North America, commented, “Once again, we saw an increase in consumable and platform sales in the second quarter. Revenue from consumables and service for the second quarter grew nearly 44% year-over-year and reached a record level.” “InMode’s Envision platform, which offers a full periorbital treatment, continued to perform well in Q2, as we gained market traction stemming from the soft launch in Canada last year,” said Dr. Spero Theodorou, Chief Medical Officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INMD:
- InMode Reports Second Quarter 2023 Financial Results; Record Quarterly Revenue of $136.1M Represents 20% Year-Over-Year Growth
- InMode Expands Women’s Health and Wellness Market Footprint through Acquisition of Viveve Patents
- InMode Stock (NASDAQ:INMD): Still Reasonably Priced Even after Going Vertical
- InMode raises FY23 revenue view to $530M-$540M from $525M-$530M
- InMode sees Q2 non-GAAP EPS 70c-71c, consensus 64c